"The product has been produced at the Company’s manufacturing facilty to the same human clinical study standards as the previously announced Phase I intravenous clinical trial. It is anticipated the two studies will run in parallel, demonstrating the broad administration capabilities of RECCE® 327."
Nice little implication that the IV trial will also be going ahead at the same time. Good to see things moving along, these are the real trials we want. A successful burns trial would be a huge derisking for the company, that alone (assuming it goes all the way) is a company maker. Something to beat all those antibiotic-resistant superbugs in hospitals while treating vulnerable open burns wounds? Sounds good.
"The product has been produced at the Company’s manufacturing...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.0¢ |
Change
-0.010(1.85%) |
Mkt cap ! $120.4M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.5¢ | 52.0¢ | $6.592K | 12.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21544 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 13818 | 4 |
View Market Depth
| Last trade - 12.46pm 27/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |